We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

6127:HKEXJOINN Laboratories (China) Co., Ltd. Class H Analysis

Data as of 2026-03-17 - not real-time

NT$40.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Technical outlook: The share price at TWD 40 sits above the 20‑day (36.33) and 50‑day (36.97) SMAs and comfortably exceeds the 200‑day SMA (26.58), indicating a short‑term upward bias. The MACD histogram remains bullish (0.152) and the RSI at 59 % suggests the stock is not yet overbought. However, volume is on a downtrend and the price is approaching the nearest resistance around TWD 41.25, which could cap upside in the near term.
Fundamental concerns: Valuation is stretched – a trailing P/E of 76.9 versus an industry average of 34.4 and a P/B of 3.73 imply the market is pricing in growth that the company has not delivered. Revenue is flat to slightly negative (‑1.6 % YoY) and operating margins are deep in the red (‑24.7 %). Debt is a major red flag: a debt‑to‑equity of 178 % and total debt of TWD 2.09 bn dwarf the TWD 0.34 bn cash balance, while both operating and free cash flow are negative. The dividend yield of 1.53 % looks attractive but the payout ratio is effectively zero, raising doubts about sustainability. Combined with an 80 % 30‑day volatility, the stock carries a high risk profile despite a modest beta.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price near technical resistance
  • Bullish MACD but declining volume
  • High volatility

Medium Term

1–3 years
Neutral
Model confidence: 4/10

Key Factors

  • Overvalued multiples relative to peers
  • Weak earnings and negative cash flow
  • Heavy leverage limiting financial flexibility

Long Term

> 3 years
Cautious
Model confidence: 6/10

Key Factors

  • Sustained high debt‑to‑equity ratio
  • Lack of clear growth catalysts in core semiconductor market
  • Dividend not supported by earnings

Key Metrics & Analysis

Financial Health

Revenue Growth-1.60%
Profit Margin5.14%
P/E Ratio76.9
ROE4.42%
ROA-3.59%
Debt/Equity177.68
P/B Ratio3.7
Op. Cash FlowNT$-148262000
Free Cash FlowNT$-100784872
Industry P/E34.4

Technical Analysis

TrendNeutral
RSI59.4
SupportNT$31.70
ResistanceNT$41.25
MA 20NT$36.33
MA 50NT$36.97
MA 200NT$26.58
MACDBullish
VolumeDecreasing
Fear & Greed Index81.25

Valuation

GradeOvervalued
TypeValue
Dividend Yield1.53%

Risk Assessment

Beta0.55
Volatility80.48%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.